Ablation of osteopontin improves the skeletal phenotype of phospho1-/- mice

Journal of Bone and Mineral Research

Volumn 29, Issue 11 S1, 2014, Pages 2369-2381

  Yadav, Manisha C ^a   Huesa, Carmen ^b   Narisawa, Sonoko ^a   Hoylaerts, Marc F ^c   Moreau, Alain ^d   Farquharson, Colin ^b   Millán, José Luis ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Genetic animal models; Growth plate; Matrix mineralization; Noncollagenous proteins; Osteomalacia; Rickets

Indexed keywords

OSTEOPONTIN; PHOSPHATASE; PHOSPHO1 PROTEIN; UNCLASSIFIED DRUG; DIFFERENTIATION ANTIGEN; PHOSPHO1 PROTEIN, MOUSE; SPP1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEFECT; BONE MINERALIZATION; CARTILAGE CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; LIQUID CHROMATOGRAPHY; LONG BONE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCOLIOSIS; SKELETON; SKELETON MALFORMATION; TANDEM MASS SPECTROMETRY; UPREGULATION; VERTEBRA; BIOACCUMULATION; BONE DENSITY; BONE DYSPLASIA; CORTICAL BONE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; PROTEIN BLOOD LEVEL; PROTEIN HYDROLYSIS; SPINE; SPINE MALFORMATION; TIBIA; TRABECULAR BONE; AGING; ANIMAL; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

AGING; ANIMALS; ANTIGENS, DIFFERENTIATION; BONE DENSITY; CALCIFICATION, PHYSIOLOGIC; CHONDROCYTES; MICE; MICE, KNOCKOUT; OSTEOPONTIN; PHENOTYPE; PHOSPHORIC MONOESTER HYDROLASES;

EID: 84919384889     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2281     Document Type: Article

References (37)

1. Stewart AJ, Roberts SJ, Seawright E, Davey MG, Fleming RH, Farquharson C. The presence of PHOSPHO1 in matrix vesicles and its developmental expression prior to skeletal mineralization. Bone. 2006;39:1000-7.
2. Roberts S, Narisawa S, Harmey D, Millán JL, Farquharson C. Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization. J Bone Miner Res. 2007;22:617-27.
3. Yadav MC, Simao AMS, Narisawa S, et al. Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res. 2011;26:286-97.
4. Huesa C, Yadav MC, Finnila MAJ, et al. PHOSPHO1 is essential for mechanically competent mineralization and the avoidance of spontaneous fractures. Bone. 2011;48:1066-77.
5. McKee MD, Yadav MC, Foster BL, Somerman MJ, Farquharson C, Millán JL. Compounded PHOSPHO1/ALPL deficiencies reduce dentin mineralization. J Dent Res. 2013;92:721-7.
6. Millán JL. The role of phosphatases in the initiation of skeletal mineralization. Calcif Tissue Int. 2013;93:299-306.
7. Murshed M, Harmey D, Millán JL, McKee MD, Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 2005;19:1093-104.
8. Millán JL, Narisawa S, Lemire I, et al. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res. 2008;23:777-87.
9. Boskey AL, Maresca M, Ulrich W, Doty SB, Butler WT, Prince CW. Osteopontin hydroxyapatite interactions in vitro. Inhibition of hydroxyapatite formation and growth in a gelatin gel. Bone Miner. 1993;22:147-59.
10. Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins; structural specificity of the osteopontinmediated inhibition of hydroxyapatite formation. Biochem J. 1994;300:723-8.
11. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med. 2000;11:279-303.
12. Hunter GK. Role of osteopontin in modulation of hydroxyapatite formation. Calcif Tissue Int. 2013;93:348-54.
13. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cellbinding sequence. Proc Natl Acad Sci USA. 1986;83:8819-23.
14. Sorensen ES, Hojrup P, Petersen TE. Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci. 1995;4:2040-9.
15. Addison WN, Masica DL, Gray JJ, McKee MD. Phosphorylationdependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res. 2010; 25:695-705.
16. Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int. 2002;71:145-54.
17. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL. Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2-/- mice. J Bone Miner Res. 2006;21: 1377-86.
18. Johnson K, Goding J, Van Etten D, et al. Linked deficiencies in extracellular PPi and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res. 2003;18:994-1004.
19. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL. Concerted regulation of inorganic pyrophosphate and osteopontin by Akp2, Enpp1, and Ank-an integrated model of the pathogenesis of mineralization disorders. Am J Pathol. 2004;164:1199-209.
20. Addison WN, Azari F, Sorensen ES, Kaartinen MT, McKee MD. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin and inhibiting alkaline phosphatase activity. J Biol Chem. 2007;282:15872-83.
21. Rittling SR, Matsumoto HN, McKee MD, et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res. 1998;13:1101-11.
22. Narisawa S, Wennberg S, Millán JL. Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization. J Pathol. 2001;193:125-33.
23. Hessle L, Johnson KA, Anderson HC, et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA. 2002;99:9445-9.
24. Prince CW, Oosawa T, Butler WT, et al. Isolation, characterization, and biosynthesis of phosphorylated glycoprotein from rat bone. J Biol Chem. 1987;262:2900-7.
25. Narisawa S, Yadav MC, Millán JL. In vivo overexpression of tissuenonspecific alkaline phosphatase increases skeletal mineralization and affects the phosphorylation status of osteopontin. J Bone Miner Res. 2013;28:1587-98.
26. Moreau A, Franco A, Azeddine B, et al. High circulating levels of osteopontin are associated with idiopathic scoliosis onset and spinal deformity progression. Presented at: 44th Annual Meeting Scoliosis Research Society; September 23-26, 2009; San Antonio, TX, USA.
27. Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002;161:2035-46.
28. Mo L, Liaw L, Evan AP, Sommer AJ, Lieske JC, Wu XR. Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. Am J Physiol Renal Physiol. 2007;293:F1935-43.
29. Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med. 2002;196:1047-55.
30. Wesson JA, Johnson RJ, Mazzali M, et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol. 2003;14:139-47.
31. Shapses SA, Cifuentes M, Spevak L, et al. Osteopontin facilitates bone resorption, decreasing bone mineral crystallinity and content during calcium deficiency. Calc Tissue Int. 2003;73:86-92.
32. Rittling SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin deficient mice. Exp Nephrol. 1999;7:103-13.
33. Liu YK, Uemura T, Nemoto A, et al. Osteopontin involvement in integrin-mediated cell signaling and regulation of expression of alkaline phosphatase during early differentiation of UMR cells. FEBS Lett. 1997;420:112-6.
34. Polewski MD, Johnson KA, Foster M, Millán JL, Terkeltaub R. Inorganic pyrophosphatase induces type I collagen in osteoblasts. Bone. 2010;46:81-90.
35. Whyte MP, Valdes R Jr, Ryan LM, McAlister WH. Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. J Pediatr. 1982;101:379-86.
36. Whyte MP, McAlister WH, Patton LS, et al. Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: results in three additional patients. J Pediatr. 1984;105: 926-33.
37. Whyte MP, Greenberg CR, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366(10): 904-13.